BioMarin Announces Third Quarter 2020 Total Revenues of $477 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BioMarin Pharma (BMRN) Tops Q3 EPS, Lowers FY Revenue Guidance
November 5, 2020 4:21 PM ESTBioMarin Pharma (NASDAQ: BMRN) reported Q3 GAAP EPS of $4.01, which may not compare to the analyst estimate of $1.29. Revenue for the quarter came in at $476.8 million versus the consensus estimate of $454.64 million.
GUIDANCE:
BioMarin Pharma sees FY2020 revenue of $1.81-1.87... More
